135 related articles for article (PubMed ID: 36938650)
1. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases.
Fujimura T; Maekawa T; Kato H; Ito T; Matsushita S; Yoshino K; Fujisawa Y; Ishizuki S; Segawa K; Yamamoto J; Hashimoto A; Kambayashi Y; Asano Y
J Dermatol; 2023 Jul; 50(7):912-916. PubMed ID: 36938650
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases.
Fujimura T; Furudate S; Maekawa T; Kato H; Ito T; Matsushita S; Yoshino K; Hashimoto A; Muto Y; Ohuchi K; Amagai R; Kambayashi Y; Fujisawa Y
Skin Health Dis; 2023 Feb; 3(1):e180. PubMed ID: 36751323
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel.
Kajihara I; Kanemaru H; Miyake T; Aoi J; Masuguchi S; Fukushima S; Jinnin M; Ihn H
Drug Discov Ther; 2015 Feb; 9(1):75-7. PubMed ID: 25788055
[TBL] [Abstract][Full Text] [Related]
6. A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K; Shibata T; Namikawa K; Takahashi A; Yokota K; Nakano E; Teramoto Y; Tsutsumida A; Maeda T; Yamazaki N;
BMC Cancer; 2020 Jul; 20(1):652. PubMed ID: 32660439
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T; Yoshino K; Nakamura M; Kato H; Ito T; Maekawa T; Fujisawa Y; Matsushita S; Amagai R; Yamazaki E; Takahashi M; Tamabuchi E; Hashimoto A; Kambayashi Y; Yamazaki N; Miyata T; Asano Y
Exp Dermatol; 2024 Jan; 33(1):e14976. PubMed ID: 37946551
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study.
Fujisawa Y; Fujimura T; Matsushita S; Yamamoto Y; Uchi H; Otsuka A; Funakoshi T; Miyagi T; Hata H; Gosho M; Kambayashi Y; Aoki M; Yanagi T; Ohira A; Nakamura Y; Maeda T; Yoshino K
Br J Dermatol; 2020 Nov; 183(5):831-839. PubMed ID: 32198756
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: A single-institution retrospective study of 21 cases.
Seo T; Kitamura S; Yanagi T; Ujiie H
J Dermatol; 2022 Mar; 49(3):383-386. PubMed ID: 34881462
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Fujisawa Y; Yoshino K; Kadono T; Miyagawa T; Nakamura Y; Fujimoto M
Br J Dermatol; 2014 Dec; 171(6):1493-500. PubMed ID: 24814962
[TBL] [Abstract][Full Text] [Related]
11. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of taxane regimens in patients with metastatic angiosarcoma.
Hirata T; Yonemori K; Ando M; Hirakawa A; Tsuda H; Hasegawa T; Chuman H; Namikawa K; Yamazaki N; Fujiwara Y
Eur J Dermatol; 2011; 21(4):539-45. PubMed ID: 21697045
[TBL] [Abstract][Full Text] [Related]
13. Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience.
Fujisawa Y; Nakamura Y; Kawachi Y; Otsuka F
J Dermatolog Treat; 2014 Oct; 25(5):419-23. PubMed ID: 23210914
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
17. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
19. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.
Park C; Kim M; Kwak Y; Moon KC; Kim SH; Keam B; Kim YJ; Kim TM; Kim DW
Cancer Res Treat; 2021 Oct; 53(4):1195-1203. PubMed ID: 33540493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
